| EPH42 Evaluating the Public Health Impact of Dengue Vaccination in Indonesia: A Dynamic Transmission Modeling Assessment amidst Uncertainties in the Implementation Strategies S Garba, YH Chen, J Lang, D Wang, I Diakite, C Palmer, E Elbasha Value in Health 27 (6), S160, 2024 | | 2024 |
| EE175 Economic Burden of Pneumococcal Disease Among US Children—A Review of Cost-Effectiveness Analyses of Pneumococcal Vaccines M Huang, J Xie, E Elbasha, S Mohanty, M Kelly Value in Health 27 (6), S90, 2024 | | 2024 |
| EE212 Evaluating the Potential Health and Economic Impact of V116, an Adult Specific 21-Valent Pneumococcal Conjugate Vaccine, on Invasive Pneumococcal Disease in the United States Z Yi, E Elbasha, K Owusu-Edusei Value in Health 27 (6), S96, 2024 | | 2024 |
| Structured Literature Review to Identify Human Papillomavirus’s Natural History Parameters for Dynamic Population Models of Vaccine Impacts I Diakite, B Martins, K Owusu-Edusei, C Palmer, O Patterson-Lomba, ... Infectious Diseases and Therapy, 1-26, 2024 | 1 | 2024 |
| Comparison of a static cohort model and dynamic transmission model for respiratory syncytial virus intervention programs for infants in England and Wales JC Lang, K Kura, SM Garba, EH Elbasha, YH Chen Vaccine 42 (8), 1918-1927, 2024 | | 2024 |
| A dynamic transmission model for assessing the impact of pneumococcal vaccination T Malik, K M Bakker, R Oidtman, O Sharomi, G Meleleo, R Nachbar, ... medRxiv, 2024.06. 11.24308671, 2024 | | 2024 |
| PCR48 Health-Related Quality of Life in Children with Pneumococcal Disease: What Can We Learn from Cost-Effectiveness Analyses of Pneumococcal Vaccines? M Huang, J Xie, S Mohanty, E Elbasha Value in Health 26 (12), S458, 2023 | | 2023 |
| PCR267 Health-Related Utilities Associated with Pneumococcal Disease in the Adult Population: What Do We Know? M Huang, J Xie, S Mohanty, E Elbasha Value in Health 26 (12), S501, 2023 | | 2023 |
| Cost-effectiveness analysis of routine use of 15-valent pneumococcal conjugate vaccine in the US pediatric population M Huang, T Hu, J Weaver, K Owusu-Edusei, E Elbasha Vaccines 11 (1), 135, 2023 | 7 | 2023 |
| 578. Cost-effectiveness of Infant Vaccination with PCV15 Compared to PCV13 in the United States M Huang, T Hu, J Weaver, K Owusu-Edusei, E Elbasha Open Forum Infectious Diseases 9 (Supplement_2), ofac492. 630, 2022 | | 2022 |
| Modeling the impact of exogenous boosting and universal varicella vaccination on the clinical and economic burden of varicella and herpes zoster in a dynamic population for … O Sharomi, I Xausa, R Nachbar, M Pillsbury, I Matthews, T Petigara, ... Vaccines 10 (9), 1416, 2022 | 5 | 2022 |
| Authors’ Reply to Comment on “Risk-Adjusted Performance Measures” EH Elbasha PharmacoEconomics 40 (7), 741-742, 2022 | | 2022 |
| Cost‑Effectiveness Risk‑Aversion Curves: Comparison of Risk-Adjusted Performance Measures and Expected-Utility Approaches EH Elbasha Pharmacoeconomics 40 (5), 497-507, 2022 | 7 | 2022 |
| Modeling the health and economic implications of adopting a 1-dose 9-valent human papillomavirus vaccination regimen in a high-income country setting: An analysis in the United … V Daniels, K Saxena, O Patterson-Lomba, A Gomez-Lievano, A Saah, ... Vaccine 40 (14), 2173-2183, 2022 | 7 | 2022 |
| Vaccination and herd immunity thresholds in heterogeneous populations EH Elbasha, AB Gumel Journal of mathematical biology 83 (6), 73, 2021 | 22 | 2021 |
| Public health impact and cost effectiveness of routine and catch-up vaccination of girls and women with a nine-valent HPV vaccine in Japan: a model-based study P Cody, K Tobe, M Abe, EH Elbasha BMC Infectious Diseases 21, 1-13, 2021 | 27 | 2021 |
| Cost-effectiveness of routine catch-up hepatitis a vaccination in the United States: Dynamic transmission modeling study EH Elbasha, Y Choi, V Daniels, MG Goveia Vaccine 39 (42), 6315-6321, 2021 | 3 | 2021 |
| Catch-up HepA vaccination reduces HepA morbidity and mortality, saves cost in the US EH Elbasha PharmacoEconomics & Outcomes News 888, 6-2, 2021 | | 2021 |
| Public health impact and cost-effectiveness of catch-up 9-valent HPV vaccination of individuals through age 45 years in the United States V Daniels, VS Prabhu, C Palmer, S Samant, S Kothari, C Roberts, ... Human Vaccines & Immunotherapeutics 17 (7), 1943-1951, 2021 | 29 | 2021 |
| Mathematical assessment of the impact of cohort vaccination on pneumococcal carriage and serotype replacement TM Malik, J Mohammed-Awel, AB Gumel, EH Elbasha Journal of biological dynamics 15 (sup1), S214-S247, 2021 | 2 | 2021 |
Salaheddin MahmudProfessor and Canada Research Chair of Pharmaco-epidemiology, University of Manitoba在 mcgill.ca 的电子邮件经过验证
